Race to stop cancer before it starts: new drug trial aims to delay deadly myeloma
NCT ID NCT07393282
Summary
This study is testing whether an experimental drug called linvoseltamab can delay or prevent the development of active multiple myeloma better than an existing drug, daratumumab. It will involve about 270 people diagnosed with high-risk smoldering multiple myeloma, a condition that often progresses to the active cancer. Researchers will compare how long it takes for the disease to progress in each group and monitor side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.